Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Bracco

Offers products, injectors and solutions portfolio for all diagnostic applications from constrast media to medical de... read more Featured Products: More products

Download Mobile App




Groundbreaking AI-Powered Software Significantly Enhances Brain MRI

By MedImaging International staff writers
Posted on 25 Oct 2024
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)

Contrast-enhanced magnetic resonance imaging (MRI) utilizes contrast agents to illuminate specific tissues or abnormalities, leading to improved visualization and more comprehensive information. Integrating artificial intelligence (AI) into this process could enhance image interpretation accuracy and efficiency, bolster diagnostic capabilities, and optimize patient care. Now, a groundbreaking AI-powered software has been designed to significantly improve brain MRI, particularly in detecting small and poorly enhanced lesions.

AiMIFY, a collaborative software from Bracco Diagnostics (Milan, Italy) and Subtle Medical (Menlo Park, CA, USA), employs advanced AI technology to increase the contrast enhancement of brain MR images by up to two times the level achieved with a standard dose of gadolinium-based contrast agents (GBCAs). This enhancement allows radiologists and neuroradiologists to obtain clearer, more detailed images, enhancing the visibility of both small and large lesions compared to standard post-contrast images. The software's efficacy has been validated across a wide range of test data, encompassing various patient demographics, pathologies, lesion sizes, MRI scanner vendors, sequences, and acquisition orientations. AiMIFY has received FDA clearance as a Class II software as a medical device (SaMD) specifically for brain MRI.

"This FDA clearance marks a significant milestone for our innovative product, showcasing its potential to transform MRI," said Fulvio Renoldi Bracco, Vice Chairman & Chief Executive Officer of Bracco Imaging S.p.A. "By integrating Bracco's expertise in contrast imaging with Subtle Medical's cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients."

"We partnered with Bracco to unlock the potential that AI brings to medical imaging," added Ajit Shankaranarayanan, PhD, Chief Product Officer at Subtle Medical. "The FDA clearance represents a significant milestone for both companies, as we join forces to empower radiological professionals and improve outcomes for patients worldwide with this innovative AI-powered medical imaging solution."

Related Links:
Bracco Diagnostics
Subtle Medical

Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Biopsy Software
Affirm® Contrast
Ultrasound Needle Guidance System
SonoSite L25
Medical Radiographic X-Ray Machine
TR30N HF

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.